Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 3Gynecologic 2Thoracic 1Sarcoma 1Other solid neoplasm 1Other hematologic neoplasm 1Myeloid 1

Conditions

Ovarian Neoplasms 1Neoplasm Metastasis 1Endometrial Neoplasms 1Carcinosarcoma 1Breast Neoplasms 1

Interventions

Radiotherapy 221Cyclophosphamide 211Doxorubicin 210Temozolomide 182Ifosfamide 121Filgrastim 111Imatinib Mesylate 104Etoposide 101Vincristine 92Gemcitabine 89Bevacizumab 83Magnetic Resonance Spectroscopy 81Irinotecan 79pembrolizumab 75Radiation 70Carboplatin 65Methotrexate 62pazopanib 61Nivolumab 58Cisplatin 58fludarabine phosphate 57Surgical Procedures, Operative 57Peripheral Blood Stem Cell Transplantation 57Specimen Handling 56Trabectedin 52Docetaxel 50Biopsy 50Busulfan 49Melphalan 46Paclitaxel 44

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
rebastinib × Sarcoma × Clear all
NCT03601897 2024-12-27

A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors

Deciphera Pharmaceuticals, LLC

Phase 1/2 Terminated
177 enrolled 25 charts
BreastGynecologicSarcoma

Breast Neoplasms, Carcinosarcoma, Neoplasm Metastasis, Ovarian Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡